PD-L1 targeted antisense oligonucleotide (University of Basel/Secarna)

N/A

Report date: 2025/01/26 17:44:26
NME

Base Information

Drug NamePD-L1 targeted antisense oligonucleotide (University of Basel/Secarna)
Drug Alias NamePD-L1 checkpoint inhibitor (University of Basel/Secarna)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSecarna Pharmaceuticals GmbH & Co KG
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of BaselSecarna Pharmaceuticals GmbH & Co KG
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A